SCIENCE THAT movesTM
Science never stands still. We drive it forward, accelerating high-impact therapies in autoimmune diseases and cancer by uniting exceptional scientific expertise, strategic risk-taking, and rigorous decision-making to improve peoples’ lives.
At Cullinan Therapeutics, we believe in a future where people living with autoimmune diseases and cancer spend less time managing their conditions and more time on what matters most.
WHERE SPEED MEETS STRATEGY
Our clinical-stage pipeline reflects a deliberate approach of advancing only the most promising molecules to address high unmet needs and achieve the greatest potential impact for people living with autoimmune diseases and cancer.
LATEST UPDATES
TARGETING CD19 IN TREATING AUTOIMMUNE DISEASES
NEW REZILIENT2 DATA AT ESMO
CULLINAN AND TAIHO PRESENT DATA ON ZIPALERTINIB
INNOVATING WITH INTENT
The best science not only moves forward — it moves people. Our approach to therapeutic innovation centers around leveraging our deep expertise in immune modulation to deliberately develop and advance therapies that deliver meaningful outcomes for patients and their loved ones.